Usual Adult Dose for Asthma

210 mg subcutaneously every 4 weeks

Comments:

• This drug is not indicated for the relief of acute bronchospasm or status asthmaticus.

Use: As add-on maintenance treatment for severe asthma.

Usual Pediatric Dose for Asthma

12 years or older: 210 mg subcutaneously every 4 weeks

Comments:

• This drug is not indicated for the relief of acute bronchospasm or status asthmaticus.

Use: As add-on maintenance treatment for severe asthma in pediatric patients 12 years or older.

Renal Dose Adjustments

Mild to moderate renal impairment: No adjustment recommended.
Severe renal impairment: Data not available

Liver Dose Adjustments

No adjustment recommended.

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active substance or any product ingredients

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Administer subcutaneously every 4 weeks into upper arm, thigh, or abdomen
• Do not inject into areas where skin is tender, bruised, erythematous, or hardened; rotate injection sites
• Intended for injection by a healthcare provider

MISSED DOSE: If a dose is missed, administer as soon as possible and resume dosing on the usual day of administration; if next dose is already due, then administer as planned

Storage requirements:

• Store refrigerated (36F to 46F [2C to 8C]); store in original carton to protect from light
• May be kept at room temperature (68F to 77F [20C to 25C]) for a maximum of 30 days; do not return to refrigerator once it has reached room temperature
• Do not freeze, do not shake, do not expose to heat

Reconstitution/preparation techniques:

• Remove from refrigerator and allow to reach room temperature (this generally takes 60 minutes)
• See manufacturer's product information for illustrated instructions on single-dose syringe administration

Patient advice:

• Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
• Patients should understand that this drug is not to treat acute asthma symptoms and they should be instructed to seek medical advice if their asthma remains uncontrolled or worsens.
• Patients should consult their healthcare provider if they are needing vaccinations.